Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker™ Technology Targeting Inflammatory Disease
Impact BioMedical Inc. (NYSE: IBO) has announced the issuance of Canadian Patent #3,024,728 for its Linebacker™ technology platform. The patent, titled "Electrophilically Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders," covers novel enhanced phenolic compounds and pharmaceutical compositions for treating inflammatory diseases.
The Linebacker™ technology targets key inflammatory pathways, potentially reducing inflammation and providing symptomatic relief with fewer side effects compared to traditional anti-inflammatory medications. The patent includes a method for using Linebacker™ formulations to inhibit inflammatory responses in conditions such as arthritis, asthma, and inflammatory bowel disease.
This is the first Linebacker™ patent issued in Canada, with an expiration date in May 2037. CEO Frank D. Heuszel highlighted the significance of this achievement, noting that the Canadian Inflammatory Disease Treatment Market was estimated at $7B in 2022.
Impact BioMedical Inc. (NYSE: IBO) ha annunciato il rilascio del Brevetto Canadese #3.024.728 per la sua piattaforma tecnologica Linebacker™. Il brevetto, intitolato "Composti Fenolici Elettronicamente Potenziati per il Trattamento di Malattie e Disturbi Infiammatori", copre nuovi composti fenolici potenziati e composizioni farmaceutiche per il trattamento delle malattie infiammatorie.
La tecnologia Linebacker™ si concentra su percorsi infiammatori chiave, potenzialmente riducendo l'infiammazione e fornendo sollievo sintomatico con meno effetti collaterali rispetto ai farmaci anti-infiammatori tradizionali. Il brevetto include un metodo per utilizzare le formulazioni Linebacker™ per inibire le risposte infiammatorie in condizioni comeArtrite, Asma e Malattia Infiammatoria Intestinale.
Questo è il primo brevetto Linebacker™ rilasciato in Canada, con una data di scadenza a maggio 2037. Il CEO Frank D. Heuszel ha sottolineato l'importanza di questo traguardo, notando che il mercato canadese per il trattamento delle malattie infiammatorie è stato stimato a 7 miliardi di dollari nel 2022.
Impact BioMedical Inc. (NYSE: IBO) ha anunciado la emisión del Patente Canadiense #3,024,728 para su plataforma tecnológica Linebacker™. La patente, titulada "Compuestos Fenólicos Mejorados Electrofílicamente para el Tratamiento de Enfermedades y Trastornos Relacionados con la Inflamación", cubre nuevos compuestos fenólicos mejorados y composiciones farmacéuticas para tratar enfermedades inflamatorias.
La tecnología Linebacker™ se dirige a vías inflamatorias clave, potencialmente reduciendo la inflamación y proporcionando alivio sintomático con menos efectos secundarios en comparación con los medicamentos antiinflamatorios tradicionales. La patente incluye un método para usar formulaciones de Linebacker™ para inhibir respuestas inflamatorias en condiciones como artritis, asma y enfermedad inflamatoria intestinal.
Esta es la primera patente de Linebacker™ emitida en Canadá, con una fecha de expiración en mayo de 2037. El CEO Frank D. Heuszel destacó la importancia de este logro, señalando que el mercado canadiense de tratamientos para enfermedades inflamatorias se estimó en 7 mil millones de dólares en 2022.
Impact BioMedical Inc. (NYSE: IBO)는 캐나다 특허 #3,024,728을 자사의 Linebacker™ 기술 플랫폼에 대한 발급을 발표했습니다. 이 특허는 "염증 관련 질병 및 장애를 치료하기 위한 전자친화적으로 강화된 페놀 화합물"이라는 제목을 가지고 있으며, 새로운 강화된 페놀 화합물과 의약품 조성물을 염증성 질병 치료에 적용합니다.
Linebacker™ 기술은 주요 염증 경로를 겨냥하여, 기존의 항염증 약물에 비해 염증을 줄이고 증상 완화를 제공할 가능성이 있습니다. 이 특허는 관절염, 천식, 염증성 장 질환과 같은 상태에서 염증 반응을 억제하는 방법을 포함합니다.
이것은 캐나다에서 발급된 최초의 Linebacker™ 특허이며, 만료일은 2037년 5월입니다. CEO Frank D. Heuszel는 이 성과의 중요성을 강조하며 2022년 캐나다 염증성 질병 치료 시장은 70억 달러로 추정되었습니다고 언급했습니다.
Impact BioMedical Inc. (NYSE: IBO) a annoncé l'octroi du Brevet Canadien #3,024,728 pour sa plateforme technologique Linebacker™. Le brevet, intitulé "Composés Phénoliques Améliorés Électrophile pour traiter les Maladies et Troubles Liés à l'Inflammation", couvre des composés phénoliques améliorés et des compositions pharmaceutiques pour traiter les maladies inflammatoires.
La technologie Linebacker™ cible les voies inflammatoires clés, permettant potentiellement de réduire l'inflammation et d'offrir un soulagement symptomatique avec moins d'effets secondaires par rapport aux médicaments anti-inflammatoires traditionnels. Le brevet inclut une méthode pour utiliser les formulations Linebacker™ afin d'inhiber les réponses inflammatoires dans des conditions telles que l'arthrite, l'asthme et la maladie inflammatoire de l'intestin.
Ceci est le premier brevet Linebacker™ émis au Canada, avec une date d'expiration en mai 2037. Le PDG Frank D. Heuszel a souligné l'importance de cette réalisation, notant que le marché canadien du traitement des maladies inflammatoires était estimé à 7 milliards de dollars en 2022.
Impact BioMedical Inc. (NYSE: IBO) hat die Erteilung des Kanadischen Patents #3,024,728 für seine Linebacker™-Technologieplattform bekannt gegeben. Das Patent mit dem Titel "Elektronisch verstärkte phenolische Verbindungen zur Behandlung von entzündungsbedingten Erkrankungen und Störungen" umfasst neuartige verstärkte phenolische Verbindungen und Arzneimittelzusammensetzungen zur Behandlung entzündlicher Krankheiten.
Die Linebacker™-Technologie zielt auf wichtige entzündliche Wege ab und könnte Entzündungen reduzieren und symptomatische Linderung bieten mit weniger Nebenwirkungen im Vergleich zu herkömmlichen entzündungshemmenden Medikamenten. Das Patent umfasst eine Methode zur Verwendung von Linebacker™-Formulierungen, um entzündliche Reaktionen zu hemmen bei Zuständen wie Arthritis, Asthma und entzündlicher Darmerkrankung.
Dies ist das erste Linebacker™-Patent, das in Kanada erteilt wurde, mit einem Ablaufdatum im Mai 2037. CEO Frank D. Heuszel hob die Bedeutung dieses Erfolges hervor und wies darauf hin, dass der kanadische Markt für die Behandlung entzündlicher Krankheiten 2022 auf 7 Milliarden Dollar geschätzt wurde.
- Issuance of Canadian Patent #3,024,728 for Linebacker™ technology
- Patent covers novel compounds and compositions for treating inflammatory diseases
- Potential for reduced side effects compared to traditional anti-inflammatory medications
- First Linebacker™ patent issued in Canada, expiring in May 2037
- Strengthens company's IP portfolio in a market estimated at $7B in 2022
- None.
Insights
The issuance of Canadian Patent #3,024,728 for Impact BioMedical's Linebacker™ technology is a significant development in the field of inflammatory disease treatment. This patent, valid until May 2037, covers novel enhanced phenolic compounds and their pharmaceutical compositions, potentially offering a new approach to managing inflammatory conditions with reduced side effects.
The Linebacker™ platform targets key inflammatory pathways, which could lead to more effective treatments for conditions like arthritis, asthma and inflammatory bowel disease. This approach may address the limitations of current anti-inflammatory medications, potentially improving patient outcomes and quality of life.
With the Canadian Inflammatory Disease Treatment Market estimated at
The patent issuance for Impact BioMedical's Linebacker™ technology in Canada is a positive development for the company's intellectual property portfolio. This strengthens IBO's position in the competitive biotech landscape and potentially creates value for shareholders in the long term.
With a market cap of
This patent could enhance IBO's attractiveness for partnerships or licensing deals, potentially generating revenue streams before product commercialization. However, the company's ability to capitalize on this opportunity will depend on its financial resources, development strategy and execution. Investors should monitor IBO's progress in advancing Linebacker™ through clinical stages and any strategic partnerships that could accelerate development or provide additional funding.
HOUSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE: IBO), is thrilled to announce a significant milestone in its innovative Linebacker™ technology platform. The Canadian Intellectual Property Office has issued Canadian Patent #3,024,728 entitled “Electrophilically Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders". This patent includes claims to novel enhanced phenolic compounds and pharmaceutical compositions as well as their uses in treating inflammatory related diseases.
The Linebacker™ technology is a platform of small molecule compounds, which target key pathways in the inflammatory process, potentially reducing inflammation and providing symptomatic relief while reducing side effects often associated with traditional anti-inflammatory medications.
This patent also employs a method of using a Linebacker™ formulation of novel compounds, with potential to inhibit the inflammatory response and mitigate conditions such as arthritis, asthma, and inflammatory bowel disease. This marks the first Linebacker™ patent issued in Canada, emphasizing Impact BioMedical’s commitment to discovering, developing, and patenting unique technologies to address unmet needs in human healthcare. The term of this Canadian patent will expire in May 2037.
Frank D. Heuszel, CEO of Impact BioMedical, commented, "The Canadian Inflammatory Disease Treatment Market was estimated to be
About Impact BioMedical Inc.:
Impact BioMedical Inc. (“IBO”) discovers, confirms, and patents unique science and technologies resulting in new offerings in human healthcare and wellness. Once available, IBO works closely with licensing, co-development, joint ventures, and other relationships to bring these offerings to market. For more information, visit Impact BioMedical Inc. | Reverse Engineering Nature (impactbiomedinc.com).
About Linebacker™ : Linebacker™ is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Polyphenols are substances found in many nuts, vegetables, and berries. Linebacker™ compounds are modified myricetin, which is a common plant-derived flavonoid. Linebacker™ down-regulates PIM (proviral integration site for Moloney murine leukemia virus) kinase which plays a key role as an oncogene in solid tumor cancers. Composition and method patents are issued for Linebacker™ in the U.S. and other countries. Linebacker™ -1 and Linebacker™ -2 compounds have been licensed to ProPhase Laboratories for development and commercialization worldwide. Linebacker™ is a trademark of Impact BioMedical Inc.
Safe Harbor Disclosure:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date.
Investor Relations:
info@impactbiomedinc.com
FAQ
What is the new Canadian patent issued to Impact BioMedical Inc. (IBO) for?
When does Impact BioMedical's (IBO) new Canadian patent for Linebacker™ technology expire?
What conditions could Impact BioMedical's (IBO) Linebacker™ technology potentially treat?
What was the estimated size of the Canadian Inflammatory Disease Treatment Market in 2022, according to Impact BioMedical (IBO)?
